Immune stimulating antibody conjugate

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

Retrieved on: 
Wednesday, December 14, 2022
Ropes & Gray, Estradiol, Office of the General Counsel for the Department of the Treasury, Roivant Sciences, Annual report, Stanford Law School, Harvard University, Security (finance), Business, Research Park at the University of Illinois Urbana-Champaign, Macrophage, Safety, Cancer, Rope, Doctor of Philosophy, Norethisterone, Bolt, Genentech, Immune stimulating antibody conjugate, ISAC, Bryn Mawr College, MBA, Research, Nivolumab, IND, General counsel, Biology, University, Patient, Business development, Management, Pharmaceutical industry

REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.
  • “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.
  • Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development.
  • Bolt Biotherapeutics’ pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs.

Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Combination therapy, Forward-looking statement, IND, Plasma, Nivolumab, U.S. Securities and Exchange Commission, Tumor microenvironment, Annual general meeting, Nasdaq, Immunotherapy, Research, File, Macrophage, Chemokine, Bolt, Neoplasm, Hand, Population, G&A, R, Annual report, Antibody, Safety, Myelocyte, Immune stimulating antibody conjugate, Operation, Biomarker, Cancer, Research and development, ISAC, Tumor-associated macrophage, Society for Immunotherapy of Cancer, Conference, Patient, Growth, Security (finance), Bristol Myers Squibb, Administration, Industry, SITC, Telescopic sight, Fine chemical, Pharmaceutical industry, Vaccine, Video game, Lease, Inc.

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Key Points: 
  • BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022
    REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.
  • Bolt Biotherapeutics Justin Kenkel, Ph.D., will present a poster entitled, BDC-3042: A Dectin-2 agonistic antibody for tumor-associated macrophage-directed immunotherapy.
  • Collaboration Revenue Collaboration revenue was $2.1 million for the third quarter ended September 30, 2022, compared to $0.8 million for the same quarter in 2021.
  • This represents 50% growth over the second quarter of 2022 as Bolt continues to ramp up activities supporting its collaborations.

Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Neoplasm, Cytokine, Nivolumab, Publication, Boston Convention and Exhibition Center, Bristol Myers Squibb, GLOBE, Society for Immunotherapy of Cancer, Poster, Chemokine, Nasdaq, Immunotherapy, Tams, Annual general meeting, Macrophage, ISAC, Doctor of Philosophy, Immune stimulating antibody conjugate, Tumor-associated macrophage, SITC, Convention center, Patient, Cancer, Pharmaceutical industry, Vaccine, IND

These new preclinical data highlight the strides we are making in the development of BDC-3042, our Dectin-2-targeting agonistic antibody, as we advance our IND-enabling activities, said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.

Key Points: 
  • These new preclinical data highlight the strides we are making in the development of BDC-3042, our Dectin-2-targeting agonistic antibody, as we advance our IND-enabling activities, said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.
  • We look forward to presenting these data to the SITC community and remain dedicated to developing novel treatments for patients with solid tumors.
  • Bolt Biotherapeutics pipeline candidates are built on the Companys deep expertise in myeloid biology and cancer drug development.
  • Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling studies.

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

Retrieved on: 
Tuesday, November 1, 2022
Conference, Cancer, GLOBE, IND, EST, Nasdaq, Macrophage, PST, Nivolumab, Immune stimulating antibody conjugate, Therapy, ISAC, Pharmaceutical industry

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, Nov. 16, 2022, at 1:15 p.m. EST (10:15 a.m. PST) in New York, New York.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, Nov. 16, 2022, at 1:15 p.m. EST (10:15 a.m. PST) in New York, New York.
  • Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer.
  • Bolt Biotherapeutics pipeline candidates are built on the Companys deep expertise in myeloid biology and cancer drug development.
  • Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling studies.

Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, August 31, 2022
Cancer, IND, Morgan, Macrophage, Nivolumab, GLOBE, ISAC, Conference, Nasdaq, Therapy, Immune stimulating antibody conjugate, Pharmaceutical industry

REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 12:20 p.m.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 12:20 p.m.
  • A live webcast of the fireside chat will be available on the Events and Presentations page of Bolts website at www.boltbio.com .
  • Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer.
  • Bolt Biotherapeutics pipeline candidates are built on the Companys deep expertise in myeloid biology and cancer drug development.

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 10, 2022
U.S. Securities and Exchange Commission, ASCO, Chemokine, GLOBE, R, Cancer, Patent, Toxicity, Clinical trial, Security (finance), Annual report, Patient, Research and development, Tumor microenvironment, Nivolumab, American Association, Industry, American Society of Clinical Oncology, Annual general meeting, Immune stimulating antibody conjugate, Safety, Operation, Nasdaq, Forward-looking statement, Bolt, Tumor-associated macrophage, Growth, Myelocyte, AACR, Bristol Myers Squibb, Immunology, ISAC, Antibody, Association, Biomarker, Population, Clinical, IND, Society, CEA, Company, Therapy, Macrophage, Administration, USPTO, Pharmaceutical industry, Vaccine, Telescopic sight, Video game, Lease, Inc.

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
  • The second quarter was one of continued progress, highlighted by steady clinical enrollment in our BDC-1001 monotherapy and combination dose-escalation studies.
  • Collaboration Revenue Collaboration revenue was $1.4 million for the quarter ended June 30, 2022, compared to $0 for the same quarter in 2021.
  • This represents 75% growth over the first quarter of 2022 as Bolt ramps up activities supporting its collaborations.

Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors

Retrieved on: 
Thursday, December 16, 2021
Forward-looking statement, Therapy, Board of directors, Ontario Institute for Cancer Research, ImmunoGen, Board, Cancer, Astellas Pharma, Industry, Nasdaq, Director, Doctor of Philosophy, SEC, University, Immune stimulating antibody conjugate, CEA, Trastuzumab, CEO, Research, Biotechnology, Patient, Safety, ISAC, ZymoGenetics, Drug development, PD-L1, Bristol Myers Squibb, Myelocyte, OSI Pharmaceuticals, Amgen, GLOBE, Antibody, Gilead Sciences, Vaccine, Pharmaceutical industry, Medical device, Pharmacology

Nicoles extensive experience in clinical development and translational research makes her an excellent addition to the Bolt Biotherapeutics Board of Directors.

Key Points: 
  • Nicoles extensive experience in clinical development and translational research makes her an excellent addition to the Bolt Biotherapeutics Board of Directors.
  • I look forward to sharing my experience and contributing to the groundbreaking work at Bolt Biotherapeutics in developing new immuno-oncology therapeutics that leverage the Boltbody ISAC platform.
  • She currently serves as an independent consultant in oncology, drug development and translational research, and on the Board of Directors at Viracta Therapeutics and Basilea Pharmaceutica.
  • In connection with Dr. Onettos appointment,Ashish Khanna, Ph.D., will be stepping down from Bolt Biotherapeutics board of directors.

Bolt Biotherapeutics Announces Changes to its Board of Directors

Retrieved on: 
Friday, November 19, 2021
Senior, NSCLC, Trastuzumab, Bristol Myers Squibb, Bolt, Lead, CEA, GLOBE, Biotechnology, Board of directors, Board, University, Forma, Immune stimulating antibody conjugate, CEO, PD-L1, Marketing, Cancer, Breast cancer, HER2, Shire (pharmaceutical company), Henley Business School South Africa, Forward-looking statement, Degenerative disease, Pfizer, IPO, Therapy, Northwest Biotherapeutics, Henley Business School, Chemical engineering, The Marketing Institute of Ireland, Merck Serono, ISAC, Patient, Genentech, Safety, Eli Lilly, Industry, Australian Marketing Institute, Novartis, SEC, Leadership, Business, Janssen, Nasdaq, Antibody, Myelocyte, Vanderbilt University, B.E, Doctor of Philosophy, NPS, Pharmaceutical industry, Vaccine

We are eager to benefit from his knowledge as we make patient-focused decisions to expand our pipeline, said Randall Schatzman, Ph.D., CEO of Bolt Biotherapeutics.

Key Points: 
  • We are eager to benefit from his knowledge as we make patient-focused decisions to expand our pipeline, said Randall Schatzman, Ph.D., CEO of Bolt Biotherapeutics.
  • Mr. OCallaghan also serves on the board of several privately held biotechnology companies, including Indaptus Therapeutics, Aquavit Therapeutics and Biocom Purchasing Group.
  • Bolt has formed a robust pipeline of immune-stimulating, myeloid-engaging therapeutics with the goal of offering long-term tumor remissions for patients.
  • I am excited to help the Bolt Biotherapeutics drive patient-focused decisions that could advance and grow the companys pipeline of product candidates.

Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, November 9, 2021
Cancer, Associate, Industry, Breast, Security (finance), Congress, Myelocyte, Society for Immunotherapy of Cancer, Serum, ESMO, Trastuzumab, Research and development, Toxicology, Bristol Myers Squibb, Safety, Biomarker, Operation, Technology, Immune stimulating antibody conjugate, Forward-looking statement, Conference, GLOBE, Annual general meeting, U.S. Securities and Exchange Commission, Research, ADCP, CEA, Patient, PD-L1, G&A, GLP, Neoplasm, R, NASDAQ, Program, Immunotherapy, Clinical research, SITC, Global Health Innovative Technology Fund, Conjugation, Administration, BMS, ISAC, Annual report, Development, Antibody, IND, Vaccine, Pharmaceutical industry, Cryptocurrency, Medical device, Lithium, Lease

REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent business highlights.

Key Points: 
  • Bolt Biotherapeutics retains the option to license global rights outside of Greater China for one program and North American rights for another program.
  • The combination portion of the trial is expected to start in the fourth quarter of 2021.
  • Collaboration Revenue Revenue was $0.8 million for the quarter ended September 30, 2021, compared to zero for the same quarter in 2020.
  • Lossfrom Operations Loss from operations was $23.5 million for the quarter ended September 30, 2021, compared to $12.4 million for the same quarter in 2020.

Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference

Retrieved on: 
Monday, November 8, 2021
PD-L1, Myelocyte, Immune stimulating antibody conjugate, ISAC, Trastuzumab, Conference, GLOBE, Antibody, CEA, Nasdaq, Patient, Vaccine

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 1:00 p.m. PT (4:00 p.m.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 1:00 p.m. PT (4:00 p.m.
  • A live webcast of the presentations will be available on the Events and Presentations page of Bolts website at www.boltbio.com .
  • Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems.
  • Bolts proprietary Boltbody Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells.